Despite the fact that the functional relevance of CD44 expression in CSCs remains to be further investigated [75], it has been shown that the knock-down of CD44 expression impacts on stem-like properties of CSC populations isolated from breast [76, 77], prostate [77], and colon cancers [69, 78], suggesting that CD44 might be a potential target for CSC-directed therapy. The gene discussed is CD44; the disease is colonic neoplasm.